Gregory D.  Gorgas net worth and biography

Gregory Gorgas Biography and Net Worth

Gregory D. Gorgas has served as our President, Chief Executive Officer and on our board of directors since April 2017. He holds three decades of successful drug development and commercialization experience in both pharmaceutical corporations and biotech companies, including more than a dozen product launches, four of which were first-in-class. Before leading Artelo, Mr. Gorgas served as Senior Vice President, Commercial and corporate officer at Mast Therapeutics, a publicly held biotechnology company, where he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular programs. Prior to that, Mr. Gorgas worked at Biogen, a publicly held biotechnology company, as Senior Director, Global Marketing with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business.   Previously he held leadership positions of increasing responsibility with IDEC Pharmaceuticals, Chiron, Cetus and Upjohn, all publicly held companies.  Mr. Gorgas currently serves as member of the board of directors at Theragence and on the advisory board of Klotho Therapeutics.  Mr. Gorgas earned a BA in economics from California State University, Northridge and, from the University of Phoenix, an MBA.

What is Gregory D. Gorgas' net worth?

The estimated net worth of Gregory D. Gorgas is at least $1,680.00 as of August 11th, 2022. Mr. Gorgas owns 1,200 shares of Artelo Biosciences stock worth more than $1,680 as of May 30th. This net worth evaluation does not reflect any other assets that Mr. Gorgas may own. Additionally, Mr. Gorgas receives a salary of $742,450.00 as CEO at Artelo Biosciences. Learn More about Gregory D. Gorgas' net worth.

How old is Gregory D. Gorgas?

Mr. Gorgas is currently 61 years old. There are 2 older executives and no younger executives at Artelo Biosciences. Learn More on Gregory D. Gorgas' age.

What is Gregory D. Gorgas' salary?

As the CEO of Artelo Biosciences, Inc., Mr. Gorgas earns $742,450.00 per year. Learn More on Gregory D. Gorgas' salary.

How do I contact Gregory D. Gorgas?

The corporate mailing address for Mr. Gorgas and other Artelo Biosciences executives is 888 Prospect Street Suite 210, La Jolla CA, 92037. Artelo Biosciences can also be reached via phone at (858) 925-7049 and via email at [email protected]. Learn More on Gregory D. Gorgas' contact information.

Has Gregory D. Gorgas been buying or selling shares of Artelo Biosciences?

Gregory D. Gorgas has not been actively trading shares of Artelo Biosciences during the last ninety days. Most recently, on Thursday, August 11th, Gregory D. Gorgas bought 1,200 shares of Artelo Biosciences stock. The stock was acquired at an average cost of $4.03 per share, with a total value of $4,836.00. Following the completion of the transaction, the chief executive officer now directly owns 1,200 shares of the company's stock, valued at $4,836. Learn More on Gregory D. Gorgas' trading history.

Gregory D. Gorgas Insider Trading History at Artelo Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2022Buy1,200$4.03$4,836.001,200View SEC Filing Icon  
4/16/2021Buy8,500$1.15$9,775.00270,676View SEC Filing Icon  
See Full Table

Gregory D. Gorgas Buying and Selling Activity at Artelo Biosciences

This chart shows Gregory D Gorgas's buying and selling at Artelo Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Artelo Biosciences Company Overview

Artelo Biosciences logo
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Read More

Today's Range

Now: $1.40
Low: $1.35
High: $1.40

50 Day Range

MA: $1.43
Low: $1.28
High: $1.58

2 Week Range

Now: $1.40
Low: $1.15
High: $2.98


10,675 shs

Average Volume

15,500 shs

Market Capitalization

$4.52 million

P/E Ratio


Dividend Yield